Jazz Pharmaceuticals PLC: Xywav IP Litigation – Generics Likely Stymied, 505(b)(2) Decision a Near-Term Risk We Highlight; Reiterate OW; PT to $253

Research evidence excerpt

Jazz Pharmaceuticals PLC: Xywav IP Litigation – Generics Likely Stymied, 505(b)(2) Decision a Near-Term Risk We Highlight; Reiterate OW; PT to $253

Equity Research

U.S. Small & Mid Cap Biotechnology

27 May 2026

Jazz Pharmaceuticals PLC

Xywav IP Litigation – Generics

Likely Stymied, 505(b)(2) Decision

JAZZ OVERWEIGHTa Near-Term Risk We Highlight;

Unchanged

U.S. Small & Mid Cap POSITIVEReiterate OW; PT to $253 Biotechnology

Expert call takeaways: robust patent estate and exclusivities Price Target USD 253.00

likely fend off generic ANDA challengers until at least 2028 raised 8% from USD 234.00

and likely longer given Xyrem parallels; 505(b)(2) filer Tris Price (26-May-26) USD 237.41 Potential Upside/Downside +6.6%

Source: Bloomberg, Barclays ResearchPharma has a more viable path, based on KOL commentary.

Market Cap (USD mn) 14895

Shares Outstanding (mn) 62.74

Free Float (%) 96.41

THE 2026 EXTEL SURVEY IS NOW OPEN 52 Wk Avg Daily Volume (mn) 0.9

Dividend Yield (%) N/A

Return on Equity TTM (%) 0.68 Support our industry-leading

Current BVPS (USD) 72.28

analysts with 5-Star votes in Source: Bloomberg

this year’s Extel All-America Price Performance Exchange-Nasdaq

Research Survey 52 Week range USD 243.32-105.00

Vote Now View Analysts

The following companies are privately held and are not under coverage by Barclays Research: Tris

Pharma. Information about these companies is being provided for information purposes only and Source: IDC

Link to Barclays Live for interactive charting

is not an investment recommendation by Barclays Research.

Bottom line: JAZZ's Xywav patent and exclusvity estate include ~22 Orange Book patents and U.S. Small & Mid Cap Biotechnology

market exclusivities that willl likely keep generics at bay until at least 2028.